Key Highlights

  • COSM shares are trading 6.99% higher at $0.25 on Wednesday, October 28, 2026.
  • Preliminary nine-month 2026 revenue was about $54.3 million, up 19% from $45.6 million.
  • Third-quarter revenue was about $17.4 million, a record for the period and up about 2% from $17.1 million.
  • Full-year 2026 revenue is expected to exceed $90 million, about 38% above 2025's $65.3 million.
  • U.S. active subscriptions reached 8,940 as of October 19, 2026.

Cosmos Health Gain: What Explains a 6.99% Rise in a Sub-$1 Stock?

Cosmos Health (NASDAQ:COSM) shares are trading 6.99% higher at $0.25 on Wednesday, October 28, 2026, which implies a prior close of about $0.23 (calculated). The stock is among the most heavily traded penny stocks of the session. No company release dated October 28 accompanies the move; the most recent news is a preliminary results release on October 7 and a shareholder letter on October 20.

Cosmos Health is a vertically integrated healthcare group incorporated in Nevada in 2009. It owns pharmaceutical and nutraceutical brands, manufactures products in the European Union through Cana Laboratories, and distributes branded generics and over-the-counter medicines to pharmacies and wholesalers in Greece and the United Kingdom. It also entered telehealth through the ZipDoctor acquisition.

Record Revenue Claim: How Does the October 7 Preliminary Update Add Up?

The company reported preliminary nine-month revenue of about $54.3 million, up 19% from $45.6 million a year earlier. Third-quarter revenue was about $17.4 million, up about 2% from $17.1 million, and every quarter of 2026 has set a record for its period. The figures are unaudited, and the full results will appear in the quarterly filing for the period ended September 30, 2026.

Full-year 2026 revenue is expected to exceed $90 million, about 38% above 2025's $65.3 million. That outlook implies fourth-quarter revenue of at least $35.7 million (calculated), roughly 81% above the $19.7 million of the prior-year quarter. Management said the fourth quarter should be the strongest in company history, driven by contract manufacturing orders, seasonal distribution strength and U.S. sales.

The contract manufacturing pipeline exceeded 32.7 million units, and the distribution arm served a network of more than 1,500 pharmacies.

U.S. Subscriptions and Margins: Can Growth Close a 12.1% Gross Margin?

In the October 20 letter, the company said it had 8,940 active U.S. subscriptions as of October 19, 2026, up 42% from 6,287 five days earlier. Monthly subscription value was about $1.33 million at standard renewal pricing, and 65.2% of U.S. checkout orders have included a subscription. The target is more than 40,000 subscriptions by year-end, with fourth-quarter U.S. revenue of about $15 million and gross profit of about $10.5 million.

Those targets contrast with 2025's gross margin of 12.1%, or $7.9 million of gross profit. The letter set 2029 targets of $200.6 million in revenue, $44.2 million in adjusted EBITDA and $31.0 million in net income. It disclosed no cash balance, but total liabilities fell 13.3% between December 31, 2025 and June 30, 2026, and the company has repurchased over 5.1 million shares for about $1.1 million under a $5.0 million program.

What to Watch Next: December 7 Nasdaq Deadline and the Third-Quarter Filing

Nasdaq granted a 180-day extension through December 7, 2026, to regain the $1.00 minimum bid price, which requires ten consecutive business days of closes above that level. With shares near $0.25, management has described a reverse split as a last resort and has not enacted one. The third-quarter filing will test the preliminary figures, and fourth-quarter results will show whether the $90 million outlook holds.